frontmind: tafasitamab lenalidomide r-chop vs r-chop for newly diagnosed high-risk dlbcl
Published 1 year ago • 208 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:20
frontmind: tafasitamab lenalidomide r-chop vs r-chop in newly diagnosed high-risk dlbcl
-
3:53
frontmind: tafasitamab lenalidomide r-chop vs r-chop in high-intermediate & high-risk dlbcl
-
1:28
first-mind: phase ib study of r-chop tafasitamab ± lenalidomide in newly diagnosed dlcbl
-
1:36
the use of tafasitamab and lenalidomide in r/r dlbcl
-
2:50
tafasitamab-lenalidomide in r/r dlbcl: clinical trial results and real-world data
-
1:35
long-term follow-up of tafasitamab and lenalidomide in r/r dlbcl
-
4:29
harvard professor believes he may have found alien technology
-
3:36
finia® fill and finish system process
-
6:10
linfoma diffuso a cellule b, con tafasitamab-lenalidomide risposte durature e sopravvivenza maggiore
-
2:23
re-mind2: observational study comparing tafasitamab lenalidomide to available therapies in r/r dlbcl
-
1:41
real-world efficacy of tafasitamab lenalidomide in r/r dlbcl & the importance of patient selection
-
3:12
tafasitamab at the blood-brain barrier: exploring this agent for the treatment of cns lymphoma
-
2:13
tafasitamab plus lenalidomide post-cd19 car-t is associated with poor outcomes in lbcl
-
2:31
long-term follow up of study of obinutuzumab, polatuzumab vedotin, and lenalidomide in r/r fl
-
1:08
an insight into the mutational landscape and unique features of cmml
-
1:26
emerging management options for aml
-
1:05
reprogramming leukemia cells into apcs as a novel therapeutic strategy for b-all
-
8:40
lenalidomide, mutations & mds outcomes
-
3:55
updates in newly diagnosed and r/r aml
-
2:03
the challenging field of hem-onc therapeutics
-
1:21
novel approaches to harnessing the immune system in lymphoma
-
0:52
inflammasome pathway: target for new treatments?